MetaCap

Moleculin Biotech (MBRX) vs Phio Pharmaceuticals (PHIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Moleculin Biotech is the larger company by market cap ($8.2 million vs $7.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBRX+1663.50%PHIO-34.37%
+2113%+986%-142%
Oct 7, 20261 yearNov 20, 2026
MBRX+1651.13%PHIO-32.98%
+1964%+916%-132%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBRX versus PHIO key metrics
MetricMBRXPHIO
Share price$7.74$0.656
Market cap$8.22M$7.84M
1-day change-2.40%-8.25%
YTD return—-37.52%
1-year return—-41.43%
5-year return—-99.56%
P/E ratio (TTM)0.04—
EPS (TTM)$179.60$-1.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-33.56M$-8.70M
52-week high$202.50$1.88
52-week low$3.22$0.6395
Distance from 52-week high-96.18%-65.11%
Analyst consensusstrong_buynone
Avg. price target upside+55.04%+2034.15%
Average volume44.66K106.09K
Shares outstanding1.06M11.95M
Employees176
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Moleculin Biotech

MBRX stock →

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Phio Pharmaceuticals

PHIO stock →

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

MBRX vs PHIO FAQ

Which is bigger, Moleculin Biotech or Phio Pharmaceuticals?

Moleculin Biotech (MBRX) is larger, with a market capitalization of $8.22M compared with $7.84M for Phio Pharmaceuticals (PHIO).

Are Moleculin Biotech and Phio Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons